Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia

NCT ID: NCT02533219

Last Updated: 2020-09-07

Basic Information

• Recruitment Status: NO_LONGER_AVAILABLE
• Study Classification: EXPANDED_ACCESS

Brief Summary

The primary objective of this study is to evaluate the utility of [18F]-DOPA PET to provide improved presurgical planning and distinguish between focal and diffuse forms of HI. The investigators will perform descriptive analysis, relying on visual analysis to diagnose and localize a focal lesion. Our findings will be compared to surgical histopathology to determine sensitivity and specificity or this technique. The investigators will also track patient surgical outcomes, specifically whether the patient is surgically "cured" or still requires medical management to control residual hypoglycemia.

Detailed Description

Hyperinsulinemic hypoglycemia is caused by low glucose due to excessive insulin secretion and remains difficult to treat because of the requirement for extensive amounts of glucose and the lack of effective long-term medical therapy. Correct diagnosis, localization, and limited excision of the focal lesion will result in a complete cure of the patient. In contrast, medically unresponsive diffuse disease requires a near total pancreatectomy, greatly increasing the risk of future diabetes mellitus. Fortunately, [18F]-DOPA PET has been shown to be a useful noninvasive imaging method for distinguishing between focal and diffuse forms of hyperinsulinemic hypoglycemia. In this study, the investigators seek to validate the effectiveness of using PET/MR and PET/CT with F-DOPA to accurately and reliably detect and localize disease.

Conditions

Hyperinsulinemic Hypoglycemia, Persistent; Congenital Hyperinsulinism; Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)

Interventions

18 F-DOPA

Subjects will undergo PET imaging with \[18F\]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of \[18F\]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.

Intervention Type: DRUG

Other Intervention Names

Fluorine-18-L-dihydroxyphenylalanine

Eligibility Criteria

Inclusion Criteria

• All Patients clinically diagnosed with Hyperinsulinemia of any age
• Patients in need of PET scan
• Patients that require sedation
• Patients that do not require sedation

Exclusion Criteria

Subjects presenting with any of the following will not be included in the study:

• Patients without Hyperinsulinemia
• Patients who are or may be pregnant
• Serious intercurrent medical illness other than hypoglycemia that precludes having the scan either because of patient instability or concerns about potential toxicity.
• Patient's requiring emergency surgical intervention that would be inappropriately delayed by [18F]-DOPA PET imaging.

• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baylor College of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Victor J. Seghers

Assistant Professor of Radiology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Texas Children's Hospital

Houston, Texas, United States

Countries

United States

Other Identifiers

H-32432

Identifier Type: -

Identifier Source: org_study_id